Ardelyx signs tenapanor license deal in Canada

19 March 2018

US drugmaker Ardelyx (Nasdaq: ARDX) has entered into license agreement with Canadian firm Knight Therapeutics (TSX: GUD) providing the latter with exclusive rights to commercialize tenapanor in Canada.

Tenapanor is Ardelyx' oral, first-in-class small molecule treatment that has completed Phase III development for irritable bowel syndrome with constipation (IBS-C) and is being evaluated in a second Phase III study for hyperphosphatemia.

Under the terms of the accord, Ardelyx is eligible to receive up to C$25 million ($19.2 million) in total payments including an upfront payment and development and sales milestones, as well as double-digit tiered royalties on net sales. Knight will have the exclusive rights to market and sell tenapanor in Canada.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK